Ipsen, a globally active biopharmaceutical company listed in Paris and in the U.S., has entered into a definitive share purchase agreement to acquire all issued and outstanding shares of Memo Therapeutics, a late-stage biotech
Tags :Memo Therapeutics
Vischer advised the main investors on the extension of Memo Therapeutics’ series C financing round, raising CHF20 million and bringing the total amount raised in the funding round to CHF 45m. Vischer’s team Vischer’
